While OS is still the king of the oncology endpoints, experts note it may soon be phased out due to the introduction of ...

Organizations can instantly repurpose compromised endpoints with IGEL OS, supported by Omnissa Horizon cloud-enabled Desktop ...

Get ready to explore the thrilling rumors surrounding Wrath of the Lich King Classic! With discussions heating up around the ...

Microsoft has acknowledged a software defect in Microsoft Defender for Endpoint that has triggered misleading security alerts on Windows 11 version 25H2.The problem incorrectly flags Dell BIOS ...

Privosegtor (also known as OCS-05) is a “first-in-class peptoid small molecule” for neuroprotective therapy for acute optic ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug ...

​Microsoft is working to resolve a bug that causes Defender for Endpoint to incorrectly tag some devices' BIOS (Basic ...

Skye Bioscience (SKYE) announced the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, its ...

The FDA is expected to decide on treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer.

A multicenter trial from the Netherlands suggests that meticulous donor selection and anaerobic stool preparation may enhance ...

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...

Enanta is advancing zelicapavir to Phase III trials after CMO Dr Scott Rottinghaus said it is justified by the Phase IIb data ...